Updated overall survival by circulating tumour DNA status from the phase 3 IMvigor010 trial: Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma

Evidence suggests that ctDNA positivity in MIUC predicts a benefit with atezolizumab. An in-progress prospective study will further evaluate these findings.